The use of robotic technology for the treatment of gait in neurological pathologies has provided different results in scientific evidence. In patients with some types of acquired brain damage, such as stroke, the use of Lokomat® therapy can bring improvements in aspects such as gait speed and balance, among other parameters and report greater functional recovery in subacute patients with greater deterioration. Similarly, the use of another technological element such as the C-Mill® reports improvements in various aspects of ambulation and balance in gait treatments for stroke patients. Likewise, the impact on the person's recovery is not only beneficial for gait rehabilitation, but also improves the perception of well-being, which can be positive in the process of readaptation to daily life.
The effect of both treatments for gait rehabilitation in adults with stroke and their impact on quality of life in the neurorehabilitation clinic will be studied.
adults with stroke and their impact on quality of life at the Lescer neurorehabilitation clinic Lescer, Madrid (Spain). Participants will be assessed at baseline, 4 weeks, 8 weeks and 12 weeks.
Diagnosis of stroke (haemorrhagic and/or ischaemic) by a specialist physician. .
Subjects who are cognitively capable and who sign the informed consent form.
Severe cognitive impairment (Mini-Mental State Examination < 24.), or impairment that prevents correct understanding of the correct understanding of the messages and explanatory orders of the treatment and its conditions.
Diagnosis of concomitant neurological diseases and craniocerebral trauma. cranioencephalic trauma.
Other diseases that interfere with the gait process (e.g. disabling arthritis or arthrosis, other neurological diseases, other neurological diseases).
Parallel
Lokomat®
DeviceTo compare the effectiveness of gait rehabilitation work in adult stroke patients using the Lokomat® tool vs. stroke with the C-Mill® tool
C-Mill
DeviceExoelectric walking aid for patients who have suffered a stroke
quality of life scale
QoL39 scale. 0 minimum - 100 maximum (higher scores mean a better outcome).
Spasticity index
Tardieu scale 0 min - 5 max (higher scores mean a worse outcome).
Click on the lead sponsor to view all of their trials.
